Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation.

Pettersen IKN, Tusubira D, Ashrafi H, Dyrstad SE, Hansen L, Liu XZ, Nilsson LIH, Løvsletten NG, Berge K, Wergedahl H, Bjørndal B, Fluge Ø, Bruland O, Rustan AC, Halberg N, Røsland GV, Berge RK, Tronstad KJ.

Mitochondrion. 2019 Jul 25;49:97-110. doi: 10.1016/j.mito.2019.07.009. [Epub ahead of print]

2.

Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.

Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, Fosså A.

Acta Oncol. 2019 Jul 9:1-8. doi: 10.1080/0284186X.2019.1637538. [Epub ahead of print]

PMID:
31286808
3.

Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Giannoccaro MP, Cossins J, Sørland K, Fluge Ø, Vincent A.

Clin Ther. 2019 May;41(5):836-847. doi: 10.1016/j.clinthera.2019.04.001. Epub 2019 May 1.

PMID:
31053295
4.

B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Fluge Ø, Rekeland IG, Lien K, Thürmer H, Borchgrevink PC, Schäfer C, Sørland K, Aßmus J, Ktoridou-Valen I, Herder I, Gotaas ME, Kvammen Ø, Baranowska KA, Bohnen LMLJ, Martinsen SS, Lonar AE, Solvang AH, Gya AES, Bruland O, Risa K, Alme K, Dahl O, Mella O.

Ann Intern Med. 2019 Apr 2. doi: 10.7326/M18-1451. [Epub ahead of print]

PMID:
30934066
5.

Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE.

Acta Oncol. 2019 May;58(5):690-699. doi: 10.1080/0284186X.2018.1558370. Epub 2019 Jan 30.

PMID:
30696346
6.

Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Rekeland IG, Fluge Ø, Alme K, Risa K, Sørland K, Mella O, de Vries A, Schjøtt J.

Clin Ther. 2019 May;41(5):806-814. doi: 10.1016/j.clinthera.2018.10.019. Epub 2018 Nov 28.

PMID:
30502905
7.

Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Günther OP, Gardy JL, Stafford P, Fluge Ø, Mella O, Tang P, Miller RR, Parker SM, Johnston SA, Patrick DM.

Mol Neurobiol. 2019 Jun;56(6):4249-4257. doi: 10.1007/s12035-018-1354-8. Epub 2018 Oct 8.

8.

Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity.

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE.

Bone Marrow Transplant. 2019 Apr;54(4):607-610. doi: 10.1038/s41409-018-0342-y. Epub 2018 Sep 27. No abstract available.

PMID:
30262906
9.

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.

Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):125-135.e3. doi: 10.1016/j.clml.2017.12.002. Epub 2017 Dec 24.

10.

Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.

Tronstad KJ, Fluge Ø, Mella O.

Tidsskr Nor Laegeforen. 2018 Jan 8;138(1). doi: 10.4045/tidsskr.17.1086. Print 2018 Jan 9. Norwegian. No abstract available.

PMID:
29313610
Free Article
11.

Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.

Fluge Ø, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, Rekeland IG, Sapkota D, Røsland GV, Fosså A, Ktoridou-Valen I, Lunde S, Sørland K, Lien K, Herder I, Thürmer H, Gotaas ME, Baranowska KA, Bohnen LM, Schäfer C, McCann A, Sommerfelt K, Helgeland L, Ueland PM, Dahl O, Tronstad KJ.

JCI Insight. 2016 Dec 22;1(21):e89376. doi: 10.1172/jci.insight.89376.

12.

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C.

Blood Cancer J. 2016 Nov 18;6(11):e501. doi: 10.1038/bcj.2016.113. No abstract available.

13.

Multimodal therapy is feasible in elderly anal cancer patients.

Dale JE, Sebjørnsen S, Leh S, Rösler C, Aaserud S, Møller B, Fluge Ø, Erichsen C, Nadipour S, Kørner H, Pfeffer F, Dahl O.

Acta Oncol. 2017 Jan;56(1):81-87. doi: 10.1080/0284186X.2016.1244356. Epub 2016 Nov 3.

PMID:
27808666
14.

Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, Mella O, Fluge Ø.

PLoS One. 2016 Aug 18;11(8):e0161226. doi: 10.1371/journal.pone.0161226. eCollection 2016.

15.

Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA.

Acta Oncol. 2016 May;55(5):547-53. doi: 10.3109/0284186X.2015.1125015.

PMID:
27123741
16.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.

PMID:
26914167
17.

Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome.

Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Fluge Ø, Mella O, Scheibenbogen C.

Brain Behav Immun. 2016 Feb;52:32-39. doi: 10.1016/j.bbi.2015.09.013. Epub 2015 Sep 21.

18.

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.

Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O.

PLoS One. 2015 Jul 1;10(7):e0129898. doi: 10.1371/journal.pone.0129898. eCollection 2015.

19.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H.

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14. No abstract available.

20.

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM.

Haematologica. 2015 Apr;100(4):534-40. doi: 10.3324/haematol.2014.108472. Epub 2014 Dec 5.

21.

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S.

PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014.

22.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.

23.

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.

PMID:
23247661
24.

Pseudoprogression in high-grade glioma.

Knudsen-Baas KM, Moen G, Fluge Ø, Storstein A.

Acta Neurol Scand Suppl. 2013;(196):31-7. doi: 10.1111/ane.12047. Review. Erratum in: Acta Neurol Scand Suppl. 2013 Mar;127(3):e17.

PMID:
23190289
25.

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O.

Br J Cancer. 2012 Nov 6;107(10):1684-91. doi: 10.1038/bjc.2012.463. Epub 2012 Oct 25.

26.

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.

Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S.

Eur J Haematol. 2012 Nov;89(5):395-402. doi: 10.1111/ejh.12005. Epub 2012 Sep 14.

PMID:
22882209
27.

[Incorrect on media strategy].

Mella O, Fluge Ø.

Tidsskr Nor Laegeforen. 2012 Feb 21;132(4):389. doi: 10.4045/tidsskr.12.0137. Norwegian. No abstract available.

28.

Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.

Myklebust MP, Fluge Ø, Immervoll H, Skarstein A, Balteskard L, Bruland O, Dahl O.

Br J Cancer. 2012 Feb 14;106(4):756-62. doi: 10.1038/bjc.2011.548.

29.

MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer.

Myklebust MP, Bruland O, Fluge Ø, Skarstein A, Balteskard L, Dahl O.

Br J Cancer. 2011 Nov 22;105(11):1719-25. doi: 10.1038/bjc.2011.457. Epub 2011 Nov 1.

30.

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O.

PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.

31.

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H.

Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Review.

PMID:
21241276
32.

Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Bruland O, Fluge Ø, Akslen LA, Eiken HG, Lillehaug JR, Varhaug JE, Knappskog PM.

BMC Cancer. 2009 Dec 8;9:425. doi: 10.1186/1471-2407-9-425.

33.

cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy.

Borkamo ED, Schem BC, Fluge Ø, Bruland O, Dahl O, Mella O.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1562-9. doi: 10.1016/j.ijrobp.2009.08.007.

PMID:
19931738
34.

Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.

Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA, Dahl O; Norwegian Gastrointestinal Cancer Group.

Br J Cancer. 2009 Oct 20;101(8):1282-9. doi: 10.1038/sj.bjc.6605333. Epub 2009 Sep 22.

35.

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.

Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z.

J Neurooncol. 2010 Feb;96(3):393-402. doi: 10.1007/s11060-009-9976-3. Epub 2009 Aug 18.

PMID:
19688297
36.
37.

Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.

Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM; Norwegian Gastrointestinal Cancer Group.

Acta Oncol. 2009;48(3):368-76. doi: 10.1080/02841860902755244.

PMID:
19242829
38.

Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor.

Borkamo ED, Dahl O, Bruland O, Fluge Ø.

Int J Hyperthermia. 2009 Feb;25(1):41-6. doi: 10.1080/02656730802397955.

PMID:
19219699
39.

Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model.

Borkamo ED, Dahl O, Bruland O, Fluge O.

Int J Hyperthermia. 2008 Aug;24(5):425-41. doi: 10.1080/02656730802081997.

PMID:
18608572
40.

Gene expression reveals two distinct groups of anal carcinomas with clinical implications.

Bruland O, Fluge O, Immervoll H, Balteskard L, Myklebust M, Skarstein A, Dahl O.

Br J Cancer. 2008 Apr 8;98(7):1264-73. doi: 10.1038/sj.bjc.6604285. Epub 2008 Mar 18.

41.

Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.

Borkamo ED, Fluge O, Mella O, Akslen LA, Bruland O, Dahl O.

Radiother Oncol. 2008 Mar;86(3):435-42. doi: 10.1016/j.radonc.2008.01.022. Epub 2008 Mar 4.

PMID:
18313158
42.

Current status of antivascular therapy and targeted treatment in the clinic.

Dahl O, Borkamo ED, Fluge O.

Int J Hyperthermia. 2008 Feb;24(1):97-110. doi: 10.1080/02656730701824406. Review.

PMID:
18214773
43.

[Anal cancer].

Dahl O, Fluge Ø.

Tidsskr Nor Laegeforen. 2008 Jan 17;128(2):198-200. Review. Norwegian.

44.

Gene expression in poorly differentiated papillary thyroid carcinomas.

Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE.

Thyroid. 2006 Feb;16(2):161-75.

PMID:
16676402
45.

Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms.

Arnesen T, Gromyko D, Horvli O, Fluge Ø, Lillehaug J, Varhaug JE.

Thyroid. 2005 Oct;15(10):1131-6.

PMID:
16279846
46.

Increased expression of genes encoding mitochondrial proteins in papillary thyroid carcinomas.

Haugen DR, Fluge Ø, Reigstad LJ, Varhaug JE, Lillehaug JR.

Thyroid. 2003 Jul;13(7):613-20.

PMID:
12964965
47.

Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure.

Reigstad LJ, Sande HM, Fluge Ø, Bruland O, Muga A, Varhaug JE, Martinez A, Lillehaug JR.

J Biol Chem. 2003 May 9;278(19):17114-20. Epub 2003 Feb 20.

48.

Dietary vitamin C intake is inversely related to cough and wheeze in young smokers.

Omenaas E, Fluge O, Buist AS, Vollmer WM, Gulsvik A.

Respir Med. 2003 Feb;97(2):134-42.

49.

NATH, a novel gene overexpressed in papillary thyroid carcinomas.

Fluge Ø, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR.

Oncogene. 2002 Aug 1;21(33):5056-68.

50.

Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue.

Fluge Ø, Haugen DR, Lillehaug JR, Varhaug JE.

World J Surg. 2001 May;25(5):623-31.

PMID:
11369990

Supplemental Content

Support Center